DALLAS--(BUSINESS WIRE)--Cothera LLC, a global medical device manufacturer, announced today it has received the CE mark for its portable VPULSE System. The VPULSE System is unique in the marketplace in that it combines intermittent pneumatic compression (IPC) for deep vein thrombosis (DVT) prevention, dynamic compression therapy, and cold therapy into a convenient, single user, post-surgical rehabilitation device for hospital, clinic and home environments. The CE mark designation will allow the VPULSE System to be sold in the European Union (EEA) and other countries that recognize or require this approval.
“The VPULSE System combines DVT prevention and post orthopedic procedure rehabilitation and places these effective therapies and significant convenience in the hands of the patients,” said General Manager Howard Edelman. “This designation recognizes Cothera’s continued commitment to provide our customers with outstanding, high quality products and puts us on a path to increase international sales.”
DVT is among the most frequent hospital-acquired conditions. Though many professional associations and hospitals have developed protocols designed to prevent DVT and PE (pulmonary embolism), until now there hasn’t been an economically feasible medical device that transitions from hospital to home use thus allowing for continued patient compliance. Given the majority of DVT episodes occur post-discharge, the VPULSE System is available to help hospitals control readmission related costs, while supporting clinician treatment plans.
About Cothera LLC - Founded in 2012, Cothera is a division of United Orthopedic Group Inc., based in Plano, Texas. The company was formed in response to market demands for better options to help prevent DVT and PE. The VPULSE System is sold internationally through medical device distributors.
Find out more at www.cothera.com.